198 related articles for article (PubMed ID: 30197796)
1. The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis.
Zhao S; Zhang M; Zhang Y; Meng H; Wang Y; Liu Y; Jing J; Huang L; Sun M; Zhang Y; Zhang Q
Cancer Biol Med; 2018 Aug; 15(3):290-298. PubMed ID: 30197796
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis.
Zeng Q; Liu Z; Liu T
BMC Cancer; 2020 Jan; 20(1):59. PubMed ID: 31992262
[TBL] [Abstract][Full Text] [Related]
3. The predictive implication of programmed cell death ligand 1 expression in extranodal natural killer/T-Cell lymphoma and its correlation with clinicopathological features: a systematic review and meta-analysis.
Li W; Zheng Q; Luo X; Zhang X; Zheng X; Yang Y
Transl Cancer Res; 2023 Aug; 12(8):2115-2127. PubMed ID: 37701117
[TBL] [Abstract][Full Text] [Related]
4. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis.
Qiu L; Zheng H; Zhao X
BMC Cancer; 2019 Mar; 19(1):273. PubMed ID: 30917792
[TBL] [Abstract][Full Text] [Related]
5. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Cai H; Zhang H; Jiang Y
Front Oncol; 2020; 10():1079. PubMed ID: 32670887
[No Abstract] [Full Text] [Related]
7. The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; He M; Zhou Y; Yang C; Wei S; Bian X; Christopher O; Xie L
Front Pharmacol; 2019; 10():139. PubMed ID: 30873025
[No Abstract] [Full Text] [Related]
8. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis.
Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y
Front Oncol; 2019; 9():897. PubMed ID: 31620360
[No Abstract] [Full Text] [Related]
9. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
10. The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
Li Y; Huang Q; Zhou Y; He M; Chen J; Gao Y; Wang X
Front Pharmacol; 2018; 9():1494. PubMed ID: 30733677
[No Abstract] [Full Text] [Related]
11. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
He J; Chen XF; Xu MG; Zhao J
Arch Oral Biol; 2020 Jun; 114():104717. PubMed ID: 32344357
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis.
Qu HX; Zhao LP; Zhan SH; Geng CX; Xu L; Xin YN; Jiang XJ
J Thorac Dis; 2016 Nov; 8(11):3197-3204. PubMed ID: 28066599
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.
Zhang F; Gong W
Int Immunopharmacol; 2020 Jun; 83():106481. PubMed ID: 32339986
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.
Pan ZK; Ye F; Wu X; An HX; Wu JX
J Thorac Dis; 2015 Mar; 7(3):462-70. PubMed ID: 25922726
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures.
Shi T; Zhu S; Guo H; Li X; Zhao S; Wang Y; Lei X; Huang D; Peng L; Li Z; Xu S
Front Oncol; 2021; 11():567978. PubMed ID: 33708622
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis.
Lu L; Li Y; Luo R; Xu J; Feng J; Wang M
Front Oncol; 2020; 10():632. PubMed ID: 32426281
[No Abstract] [Full Text] [Related]
18. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients.
Li H; Xu Y; Wan B; Song Y; Zhan P; Hu Y; Zhang Q; Zhang F; Liu H; Li T; Sugimura H; Cappuzzo F; Lin D; Lv T;
Transl Lung Cancer Res; 2019 Aug; 8(4):429-449. PubMed ID: 31555517
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.
Zhang M; Dong Y; Liu H; Wang Y; Zhao S; Xuan Q; Wang Y; Zhang Q
Sci Rep; 2016 Nov; 6():37933. PubMed ID: 27892511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
